When Cancer Gets Political

Article

Cancer moves fast; we need to move faster. Help make sure patients have access to important diagnostic tests.

When you get a cancer diagnosis, your whole world flips upside down. Your focus shifts to treatments, side effects, scans and statistics. Sometimes, however, politics creep in.

The Food and Drug Administration has just announced that it plans to begin a new level of oversight for laboratory developed tests (LDTs). I, and many others with cancer, think this is a terrible idea.

But wait, you say, isn't FDA oversight a good thing? We all want to stay safe!

Absolutely! I want to know that I am safe, and oversight is necessary and beneficial!

However, there already is oversight. These laboratories currently undergo a certification process by the Centers for Medicare and Medicaid services, as well as other accreditation agencies. This new FDA regulation adds an additional, time-consuming hoop that will slow down testing of things like cancer mutations.

Those of us with metastatic cancer don't have years to wait for FDA approval of these genetic tests.

I have a rare mutation that drives my cancer's growth, and I am currently living well on a daily pill developed to target that mutation. When my lung cancer finds a way around this pill - which it inevitably will - I will be counting on these laboratories to test that cancer growth and find a new treatment for me. Cancer moves fast; we need to move faster.

Our understanding of cancer is developing at an incredible rate, and laboratories need the freedom to react quickly, developing and tweaking these tests without having their hands tied by slow, unnecessary extra oversights.

Fellow stage 4 lung cancer patient Janet Freeman-Daily wrote eloquently about this proposed legislation: "Of course, we all want LDTs to be as validated, accurate and clinically relevant as possible. However, we also want the laboratories where these clinical testing services are performed to be able to exercise the flexibility, innovation and medical judgment necessary for good outcomes in thousands of cancer patients. This isn’t possible with the proposed FDA regulations."

Have you had genetic testing? Has you tumor been tested for mutations? This new legislation could stand in the way of that happening for you or others in the future.

If you have cancer, this impacts you.

If a family member has cancer, this is important.

Please take a moment to sign the petition, and encourage those who care about you to do the same.

(Still not sure? At least click the link below and read more about the reasoning behind this petition. It could change the course of your life.)

Tell the FDA to withdraw its proposed regulations for laboratory developed tests (LDTs). These regulations could limit patient access to life-saving tests and therapies.

The link: http://chn.ge/1uN2e2Z

Tori Tomalia is many things: a mom, a wife, a theatre artist, a mediocre cook, a Buffy fan, a stinky cheese aficionado. She is also, unfortunately, a repeat visitor to Cancerland. Stay tuned for her continued adventures (http://www.curetoday.com/community/tori-tomalia).You can follow her blog at "A Lil Lytnin' Strikes Lung Cancer" http://lil-lytnin.blogspot.com/

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content